Deploying Precision Medicine to Treat Rheumatoid Arthritis
- ABS
- Jul 2
- 1 min read
ABS CEO Eugene Williams joined Force Family Office for a webinar on precision medicine, biomarker-guided diagnosis, and ABS's immuno-corrective approach to autoimmune disease.
ABS CEO Eugene Williams recently joined Force Family Office for a webinar on ABS's precision approach to autoimmune disease — an approach rooted in precision medicine, not broad immunosuppression. Today, 30–50% of patients with rheumatoid arthritis, lupus, type 1 diabetes, and other autoimmune diseases don't respond to standard-of-care therapy. In the conversation, Eugene shared how ABS's proprietary biomarker platform identifies likely non-responders before treatment begins, and how ABS's immuno-corrective approach is designed to correct the underlying biological driver of non-response — without adding to immunosuppression risk.
An estimated 25 million people with autoimmune disease
currently don't respond to treatment.
Watch the Full Webinar
“Deploying Precision Medicine to Treat Rheumatoid Arthritis" — a co-branded ABS x Force Family Office conversation on identifying non-responders early and correcting the biology driving treatment resistance.
